The Role of Neuregulin and Stem Cells as Therapy Post-Myocardial Infarction.

Coronary artery disease, including myocardial infarction, is a leading cause of morbidity and mortality in the United States. Due to the limited self-renewal capacity of cardiac tissue, myocardial infarctions can lead to progressive heart disease with a lasting impact on health and quality of life. The recent discovery of cardiac stem cells has incited research into their potential therapeutic applications for patients suffering from cardiovascular disease. Studies have demonstrated the ability of stem cells to both generate cardiac tissues in vitro and aid in the recovery of cardiovascular function in vivo in animal models. However, the long-term efficacy of stem cells as regenerative therapy is still unknown. Exploration of alternative therapies is underway, including the use of cardiac growth factor Neuregulin-1. Research has demonstrated that Neuregulin-1 not only has direct effects on cardiomyocytes, but also acts within the tissues supporting the cardiomyocytes. Transplantation of Neuregulin-1 into ischemic cardiac tissue mitigates the progression of heart failure and can reverse cardiac remodeling. Recent publications have sought to study the combined use of these agents, and while the results are promising, they do warrant further research. This review aims to consider these therapies separately as well as in combination.